The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Oncolytic viruses in cancer therapy
Open accessAbstract
Oncolytic virotherapy is a promising form of gene therapy for cancer, employing nature’s own agents to find and destroy malignant cells. The purpose of this review is to provide an introduction to this very topical field of research and to point out some of the current observations, insights and ideas circulating in the literature. We have strived to acknowledge as many different oncolytic viruses as possible to give a broader picture of targeting cancer using viruses. Some of the newest additions to the panel of oncolytic viruses include the avian adenovirus, foamy virus, myxoma virus, yaba-like disease virus, echovirus type 1, bovine herpesvirus 4, Saimiri virus, feline panleukopenia virus, Sendai virus and the non-human coronaviruses. Although promising, virotherapy still faces many obstacles that need to be addressed, including the emergence of virus-resistant tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sarinella, F., Calistri, A., Sette, P., Palù, G., & Parolin, C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302770 · Cited by 30
RetractedDown-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Almilaji, A., Szteyn, K., Fein, E., Pakladok, T., Munoz, C., Elvira, B., Towhid, S. T., Alesutan, I., Shumilina, E., Bock, C.-T., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350083 · Cited by 8,675
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Rowe, W. P., Huebner, R. J., Gilmore, L. K., Parrott, R. H., & Ward, T. G. (1953) · Experimental Biology and Medicine · doi:10.3181/00379727-84-20714 · Cited by 1,114
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
“In this way, many conditionally-replicative AdVs have been developed to target high-replicating cell populations or cell populations with specific oncogenic mutations.(165) In 1996, ONYX-015 became the first replication-selective AdV to enter clinical trials.”
BackgroundClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
The Role of Phenolic Compounds in the Fight against Cancer – A Review
Carocho, M., & Ferreira, I. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990301 · Cited by 267
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Metadata
- Authors
- Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 254
- Issue
- 2
- Pages
- 178-216
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2081689148
- Cited by
- 333
- References
- 181
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.